REVVITY, INC
In the published model solve dated 2026-Q2, anchored at $128.80, REVVITY, INC (RVTY) is priced for today's economics sustained for ~7.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Revvity is a life-sciences and diagnostics company whose reported operating margin near 12% understates the business, because it carries heavy acquisition amortization on top of a higher underlying profitability. • The price sits at the very top of its peer distribution, paying about 42 times trailing operating income, the steepest multiple in its analytical-tools cohort. • The watch item is capital allocation and portfolio reshaping: Revvity is divesting its China immunodiagnostics business f
Is RVTY overvalued? See what's priced in →
481 institutional managers reported holding RVTY in 13F filings for the quarter ended 2026-03-31. 59 opened new positions that quarter. Held by Vanguard Group, T. Rowe Price, Janus Henderson, among others. On the short side, 8.3M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (6.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RVTY's share count is about flat over the past five years ($1.78B of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (17 and counting); the current rate is $0.28 a share annually. Cash returned over the past three years: $92.42M in dividends and $1.39B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at RVTY over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
RVTY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-13 | -6.6% | +5.6% |
| 2023-08-10 | +1.9% | -12.7% |
| 2023-11-08 | -15.2% | +31.1% |
| 2024-05-08 | +0.9% | +3.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
RVTY's latest 8-K filings: 2026-08-04 (items 2.02, 8.01, 9.01); 2026-05-05 (items 2.02, 8.01, 9.01); 2026-05-01 (items 5.03, 5.07, 9.01); 2026-02-02 (items 2.02, 9.01); 2026-01-13 (items 2.02, 7.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.